<DOC>
	<DOCNO>NCT01997450</DOCNO>
	<brief_summary>This post-marketing case-controlled study effectiveness quadrivalent live attenuate influenza vaccine ( Q/LAIV/FluMist® Quadrivalent ) versus Inactivated Influenza Vaccine ( IIV ) No Vaccine subject 2-17 year age .</brief_summary>
	<brief_title>A Case Control Study Effectiveness Q/LAIV Versus Inactivated Influenza Vaccine No Vaccine Subjects 2-17 Years Age</brief_title>
	<detailed_description>This post-marketing study enroll approximately 5,200 subject 2-17 year age seek care outpatient set febrile acute respiratory illness . This study begin fall 2013 complete 4 influenza season ( i.e.after 2016-2017 influenza season ) . No investigational product administer study . A nasal swab obtain test presence influenza virus viral pathogen . This study conduct 4 site United States America . The duration study participation subject one day .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Communitydwelling child adolescent 2 17 year age . Written Informed Consent Assent . Acute respiratory illness document study visit home fever ( oral temperature ≥ 100.0° Fahrenheit study visit , history fever report parent , use antipyretic prior study visit ) Symptom onset less 5 day prior study visit . Subject and/or subject 's legal representative able understand comply requirement protocol judged investigator . Treatment antiviral drug influenza ( oseltamivir Tamiflu® , zanamivir Relenza® ) 14 day enrollment Any condition , opinion investigator , would interfere interpretation subject safety study result Concurrent enrollment another clinical study Patient already enrol influenza season Employees clinical study site individual involve conduct study , immediate family member individual .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Q/LAIV/FluMist® Quadrivalent Vaccine , Inactivated Influenza Vaccine ( IIV ) , Effectiveness , Influenza</keyword>
</DOC>